Applications of Ethyl (R)-Nipecotate L-Tartarate in Industrial Manufacturing

As the original manufacturer, we supply Ethyl (R)-Nipecotate L-Tartarate direct to specialized sectors where downstream partners require advanced building blocks for targeted synthesis. All application scenarios below reflect established industrial practice and are supported by regulatory guidance, technical references, and integration into existing production lines.

1. Chiral Intermediate for CNS Active Pharmaceutical Ingredients

Pharmaceutical companies adopt Ethyl (R)-Nipecotate L-Tartarate as a stereocontrolled precursor in the synthesis of certain central nervous system (CNS) APIs, especially in processes where enantioselective purity directly determines the pharmacodynamic profile of the final drug. The material’s high chiral integrity is maintained from initial charge through resolution and elaboration reactions, fitting stringent cGMP conditions in regulated drug substance production.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US Pharmacopeia (USP) General Chapters <825> and <941> for chiral purity
• European Pharmacopoeia, section 2.2.34 Chromatographic Separation Techniques
• FDA 21 CFR Part 211 – Finished Pharmaceuticals

Typical usage ratio

• Used at 0.8–2.5 molar equivalents relative to the final API scaffold; ratio selected based on target enantiomeric excess and downstream yield efficiency

Downstream process integration

• Introduced in the early-stage synthesis route as the sole chiral pool reagent for asymmetrical hydrogenation, lactam ring construction, or amidation steps within API manufacturing campaigns

Final product types

• Enantiomerically pure antiepileptics, antipsychotics, and CNS stimulant APIs

2. Precursor in Stereospecific Agrochemical Synthesis

Agricultural chemical manufacturers utilize the raw material as a chiral intermediate in multi-step synthesis of select crop protection agents. Its dual functional groups contribute to the regioselective layout of active compounds, optimizing field performance and regulatory acceptance in target pesticide formulations requiring low impurity profiles.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP) for agrochemical development
• EPA 40 CFR Part 158 – Data Requirements for Pesticide Registration (for US)
• ISO 9001:2015 Quality Management System for agrochemical manufacturing
• REACH Regulation (EC) No 1907/2006—Europe

Typical usage ratio

• 0.5–2.0% w/w of total precursor mass in technical concentrate formulas; actual amount refined by in-process chiral analysis and yield optimization during upscaling

Downstream process integration

• Enters the core synthesis after initial halogenation, acting as the critical chiral donor in step-wise construction of target isomeric pesticides or herbicide molecules

Final product types

• Chiral crop protection agents and herbicide technical concentrates destined for formulation and dilution by end users

3. API Intermediate in Custom Synthesis for Contract Manufacturing

CDMOs and custom synthesis operations specify Ethyl (R)-Nipecotate L-Tartarate for use in contracted projects requiring stereospecific intermediates. By integrating it during medicinal chemistry campaigns, contract manufacturers deliver client-requested molecules that adhere to exact chiral purity targets as verified by independent batch release testing and full traceability audits.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP) as per ICH Q7
• ISO 13485 for contract manufacture of pharmaceutical development intermediates
• DMF registration requirements (Type II US FDA, CEP Europe) as appropriate for disclosed projects
• Client-specific technical agreements/quality agreements for project management

Typical usage ratio

• 1.0–3.0 equivalents, with process engineers adjusting input to deliver specified intermediate amounts for small-molecule libraries and kilo-lab scale-up

Downstream process integration

• Dosed into key asymmetric steps such as stereoselective alkylations or amidations, tracked by lot-specific analytical release and used according to project-specific batch records

Final product types

• Pharmaceutical intermediates for new chemical entities (NCEs) and reference compounds for preclinical R&D

4. Building Block in Active Ingredient Synthesis for Veterinary Medicines

Veterinary pharma producers source the material for manufacturing APIs targeting animal health, applying its chiral properties to deliver molecules with reduced off-target effects and better systemic availability in veterinary formulations. Its integration supports quality control requirements across regional compliance regimes for large- and small-animal drug production.

Industry compliance standards

• VICH GL10 GMP for Veterinary Pharmaceutical Products
• European Pharmacopoeia, chapter 5.2.4 for veterinary drugs
• US FDA 21 CFR 514 – New Animal Drug Applications
• WHO Guidelines for Veterinary Drug Manufacturers

Typical usage ratio

• Usually introduced at 0.6–1.8 molar equivalents versus target intermediates, selection based on animal species, therapeutic index, and specific synthetic route control

Downstream process integration

• Charged into the chiral resolution or alkylation step when building key functionalized rings or side chains specific to veterinary pharmaceutical APIs

Final product types

• APIs for veterinary anti-infectives, antiparasitics, and specialty companion animal drugs